ATAI — AtaiBeckley Inc.
$2.6B market cap · 0 upcoming readouts tracked
Clinical trial readout dates for AtaiBeckley Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
Target dates already passed
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 2 VLS-01 Treatment Resistant Depression | August 1, 2026 Ongoing |
| Phase 3 BPL-003 Resistant Depression | November 2026 Trial Planned |
Companies working on similar indications
Discussion
No messages yet. If you follow ATAI, you can start the conversation.
Track ATAI in real time
See live implied volatility for
ATAI and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ATAI